TC BIOPHARM (HOLDINGS) PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.57 USD | +6.80% |
|
+6.15% | -50.47% |
| Sales 2022 | 3.84M 4.8M 6.57M | Sales 2023 | - | Capitalization | 1.35M 1.69M 2.31M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.25M -1.71M | Net income 2023 | -5M -6.25M -8.54M | EV / Sales 2022 | 0.26 x |
| Net cash position 2022 | 2.01M 2.51M 3.44M | Net cash position 2023 | 661K 826K 1.13M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.57
x | P/E ratio 2023 |
-0.13
x | Employees | 41 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.24% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +6.80% | ||
| 1 week | +6.15% | ||
| Current month | +19.85% | ||
| 1 month | +10.56% | ||
| 3 months | +10.56% | ||
| 6 months | -77.12% | ||
| Current year | -50.47% |
1 week
1.44
1.67
1 month
1.183.27
Current year
0.853.35
1 year
0.8526.60
3 years
0.853 500.00
5 years
0.853 500.00
10 years
0.853 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Leek
FOU | Founder | 64 | 12-12-31 |
Bryan Kobel
CEO | Chief Executive Officer | 44 | 21-05-31 |
Martin Thorp
DFI | Director of Finance/CFO | 72 | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Bonyhadi
BRD | Director/Board Member | 70 | 22-02-21 |
Martin Thorp
DFI | Director of Finance/CFO | 72 | 14-12-31 |
Arlene Morris
CHM | Chairman | 72 | 22-02-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.53 | -2.55% | 71,794 |
| 24-04-25 | 1.57 | +6.80% | 143,462 |
| 24-04-24 | 1.47 | -6.96% | 114,078 |
| 24-04-23 | 1.58 | 0.00% | 113,576 |
| 24-04-22 | 1.58 | +6.83% | 145,337 |
End-of-day quote Nasdaq, April 24, 2024
More quotes
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Companyâs pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
| 1st Jan change | Capi. | |
|---|---|---|
| -50.47% | 4.89M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- TCBP Stock
